中
Home
About Us
About Haihe Biopharma
Mission and Vision
Management Team
Company Milestones
Awards
Research & Development
Strong, Innovation-driven R&D Capabilities
R&D Pipeline
Investor Partnerships & BD
Investors
Business Development
News Center
News
Interview
Career
Our Culture
Salary and Benefits
Employee
Job
中文
日本語
News Center
Press Release
页索引超出范围
Press Release
2018.12.08
HaiHe Biopharma Successfully Convened theNational Investigator Meeting on the Pivotal Phase IIbClinical Trial of Lucitanib AL3810-202 forTreatment of Thymic Cancer.
2018.11.28
The Site Initiation Visit Meeting of the Pivotal Phase II Clinical Trial of Simmitecan from HaiHe Biopharma is Successfully Convened in Huashan Hospital Shanghai Fudan University
2018.10.27
HaiHe Biopharma’s Obtained CTA from CNDA for the International Multi-Center Phase III Clinical Trial of the Paclitaxel RMX3001 for Treatment of Breast Cancer.
2018.10.15
HaiHe Biopharma Convened the National Investigator Meeting on the Phase III Clinical Trial of ON101
2018.07.27
HaiHe Biopharma’s Oral Paclitaxel RMX3001 Granted Clinical Trial Approval by CNDA
2018.07.26
Innovative Anti-tumor PI3Kα Inhibitor CYH33 Developed by HaiHe Biopharma Completed Dosing of the First Cancer Patient
2018.05.07
Haihe Biopharma obtains the IND Approval from FDA for its innovative IDH1 inhibitor
2020.03.17
HaiHe Biopharma Obtains the IND Implied License from FDA for its Innovative Drug EZH1/2 Dual Inhibitor
6
7
8
Interview
|
Legal statement
|
Disclaimers
|
Contact
|
Follow Us
©
2020 All Rights Reserved Haihe Biopharma Co., Ltd.
沪ICP备12016151号-1
.jpg)
